https://www.lupin.com/ monthly 1.0 https://www.lupin.com/about-us/ monthly 0.9 https://www.lupin.com/about-us/our-purpose/ monthly 0.9 https://www.lupin.com/about-us/quality-in-action/ monthly 0.9 https://www.lupin.com/about-us/our-values/ monthly 0.9 https://www.lupin.com/about-us/compliance-ethics-governance/ monthly 0.9 https://www.lupin.com/about-us/global-presence/ monthly 0.9 https://www.lupin.com/about-us/global-technical-operations monthly 0.9 https://www.lupin.com/about-us/our-science/ monthly 0.9 https://www.lupin.com/about-us/leadership/ monthly 0.9 https://www.lupin.com/about-us/leadership/alfonso-zulueta/ monthly 0.9 https://www.lupin.com/about-us/leadership/dr-abdelaziz-toumi/ monthly 0.9 https://www.lupin.com/about-us/leadership/jeffrey-kindler/ monthly 0.9 https://www.lupin.com/about-us/leadership/kbs-anand/ monthly 0.9 https://www.lupin.com/about-us/leadership/manju-gupta/ monthly 0.9 https://www.lupin.com/about-us/leadership/mark-d-mcdade/ monthly 0.9 https://www.lupin.com/about-us/leadership/punita-lal/ monthly 0.9 https://www.lupin.com/about-us/leadership/ramesh-swaminathan/ monthly 0.9 https://www.lupin.com/about-us/leadership/vinita-gupta/ monthly 0.9 https://www.lupin.com/about-us/leadership/nilesh-gupta/ monthly 0.9 https://www.lupin.com/about-us/leadership/christoph-funke/ monthly 0.9 https://www.lupin.com/about-us/leadership/claus-jepsen/ monthly 0.9 https://www.lupin.com/about-us/leadership/cyrus-karkaria/ monthly 0.9 https://www.lupin.com/about-us/leadership/dr-fabrice-egros/ monthly 0.9 https://www.lupin.com/about-us/leadership/dr-ranjana-pathak/ monthly 0.9 https://www.lupin.com/about-us/leadership/rajeev-sibal/ monthly 0.9 https://www.lupin.com/about-us/leadership/rajender-kamboj/ monthly 0.9 https://www.lupin.com/about-us/leadership/shahin-fesharaki/ monthly 0.9 https://www.lupin.com/about-us/leadership/sofia-mumtaz/ monthly 0.9 https://www.lupin.com/about-us/leadership/spiro-gavaris/ monthly 0.9 https://www.lupin.com/about-us/leadership/thierry-volle/ monthly 0.9 https://www.lupin.com/about-us/leadership/yashwant-mahadik/ monthly 0.9 https://www.lupin.com/about-us/awards-and-recognition/ monthly 0.9 https://www.lupin.com/about-us/our-manufacturing-sites/ monthly 0.9 https://www.lupin.com/about-us/global-technical-operations/ monthly 0.9 https://www.lupin.com/our-business/ monthly 0.9 https://www.lupin.com/our-business/global-generics/ monthly 0.9 https://www.lupin.com/our-business/emerging-markets/ monthly 0.9 https://www.lupin.com/our-business/india/ monthly 0.9 https://www.lupin.com/our-business/india/patient-support-programs/ monthly 0.9 https://www.lupin.com/our-business/specialty/ monthly 0.9 https://www.lupin.com/our-business/biosimilars/ monthly 0.9 https://www.lupin.com/our-business/our-adjacencies/ monthly 0.9 https://www.lupin.com/investors/ monthly 0.8 https://www.lupin.com/investors/analyst-coverage/ monthly 0.8 https://www.lupin.com/investors/code-of-conduct/ monthly 0.8 https://www.lupin.com/investors/committees-of-the-board/ monthly 0.8 https://www.lupin.com/investors/disclosure-under-regulation-46-of-sebi-regulations-2015/ monthly 0.8 https://www.lupin.com/investors/dividend/ monthly 0.8 https://www.lupin.com/investors/financials/ monthly 0.8 https://www.lupin.com/investors/iepf-saksham-niveshak/ monthly 0.8 https://www.lupin.com/investors/investor-faqs/ monthly 0.8 https://www.lupin.com/investors/news-events/ monthly 0.8 https://www.lupin.com/investors/notices/ monthly 0.8 https://www.lupin.com/investors/policies/ monthly 0.8 https://www.lupin.com/investors/reports-filings/ monthly 0.8 https://www.lupin.com/investors/share-price/ monthly 0.8 https://www.lupin.com/investors/shareholding-pattern/ monthly 0.8 https://www.lupin.com/investors/subsidiaries/ monthly 0.8 https://www.lupin.com/investors/transfer-of-physical-shares-re-lodgement/ monthly 0.8 https://www.lupin.com/investors/unclaimed-dividend/ monthly 0.8 https://www.lupin.com/investors/employee-stock-option-schemes/ monthly 0.8 https://www.lupin.com/investors/other-statutory-information/ monthly 0.8 https://www.lupin.com/investors/tips-for-shareholders/ monthly 0.8 https://www.lupin.com/sustainability/ monthly 0.8 https://www.lupin.com/community/ monthly 0.8 https://www.lupin.com/media/ monthly 0.8 https://www.lupin.com/media/media-coverage/ monthly 0.8 https://www.lupin.com/media/media-kit/ monthly 0.8 https://www.lupin.com/media/perspectives/ monthly 0.8 https://www.lupin.com/media/perspectives/a-call-to-action-bridging-mental-health-gaps-in-india-inclusively/ monthly 0.6 https://www.lupin.com/media/perspectives/a-diagnosis-doesnt-have-to-take-your-breath-away/ monthly 0.6 https://www.lupin.com/media/perspectives/a-healthy-india/ monthly 0.6 https://www.lupin.com/media/perspectives/a-score-card-for-the-pharmacy-for-the-world/ monthly 0.6 https://www.lupin.com/media/perspectives/abdelaziz-ceo-lupin-manufacturing-solutions-interview-pharma-cdmo-express-healthcare/ monthly 0.6 https://www.lupin.com/media/perspectives/abdelaziz-toumi-interview-biovoice-news-jan-2025-issue-integration-of-ai-and-ml-to-play-a-critical-role-in-reshaping-pharma-manufacturing-operations/ monthly 0.6 https://www.lupin.com/media/perspectives/accelerating-action-for-womens-health/ monthly 0.6 https://www.lupin.com/media/perspectives/ai-is-aiding-in-faster-and-better-decision-making/ monthly 0.6 https://www.lupin.com/media/perspectives/analysing-the-top-3-factors-contributing-to-diabetes-in-india-and-how-to-address-them/ monthly 0.6 https://www.lupin.com/media/perspectives/asthma-care-delivering-on-peoples-right-to-breathe/ monthly 0.6 https://www.lupin.com/media/perspectives/asthma-education-in-india-a-call-for-action/ monthly 0.6 https://www.lupin.com/media/perspectives/asthma-myths-that-take-your-breath-away/ monthly 0.6 https://www.lupin.com/media/perspectives/beyond-the-pills-how-remote-cardiac-rehab-transforms-post-hospital-recovery/ monthly 0.6 https://www.lupin.com/media/perspectives/breaking-down-barriers-to-build-a-brighter-future-for-pharma/ monthly 0.6 https://www.lupin.com/media/perspectives/building-a-resilient-future-for-indias-lungs/ monthly 0.6 https://www.lupin.com/media/perspectives/cardiac-care-in-post-covid-19-era/ monthly 0.6 https://www.lupin.com/media/perspectives/cardiologist-dr-purabi-koch-on-heart-diseases-and-women/ monthly 0.6 https://www.lupin.com/media/perspectives/christoph-funke-interview-et-pharma-building-a-tech-driven-operations-eco-systems-to-adapt-to-global-shifts-25-02-2025/ monthly 0.6 https://www.lupin.com/media/perspectives/climate-change-is-affecting-occupational-safety-too/ monthly 0.6 https://www.lupin.com/media/perspectives/comprehensive-womens-health-a-holistic-approach-to-wellness/ monthly 0.6 https://www.lupin.com/media/perspectives/digital-innovation-the-key-to-affordable-patient-first-healthcare/ monthly 0.6 https://www.lupin.com/media/perspectives/digital-intelligence-accelerates-drug-discovery/ monthly 0.6 https://www.lupin.com/media/perspectives/digital-therapeutics-digital-revolution-in-healthcare/ monthly 0.6 https://www.lupin.com/media/perspectives/digital-therapeutics-revolutionizing-womens-cardiac-health/ monthly 0.6 https://www.lupin.com/media/perspectives/driving-sustainability-and-innovation/ monthly 0.6 https://www.lupin.com/media/perspectives/emotional-sustainability-the-next-frontier-in-workplace-wellbeing/ monthly 0.6 https://www.lupin.com/media/perspectives/employees-are-at-the-front-line-of-cyber-attacks/ monthly 0.6 https://www.lupin.com/media/perspectives/empowering-womens-heart-health-breaking-barriers-and-building-a-healthier-future/ monthly 0.6 https://www.lupin.com/media/perspectives/enabling-employee-safety-in-pharmaceutical-manufacturing/ monthly 0.6 https://www.lupin.com/media/perspectives/evolution-of-the-diagnostics-industry-new-trends-models-transforming-healthcare-industry/ monthly 0.6 https://www.lupin.com/media/perspectives/from-risk-to-resilience-tackling-cardiovascular-challenges/ monthly 0.6 https://www.lupin.com/media/perspectives/from-the-power-of-the-present-to-the-hope-of-the-future/ monthly 0.6 https://www.lupin.com/media/perspectives/head-and-neck-cancer-awareness-month-why-a-patient-centric-approach-is-crucial/ monthly 0.6 https://www.lupin.com/media/perspectives/how-can-we-work-towards-better-mental-health-as-a-society/ monthly 0.6 https://www.lupin.com/media/perspectives/how-indian-pharma-is-building-a-sustainability-framework-for-a-greener-future/ monthly 0.6 https://www.lupin.com/media/perspectives/how-technology-is-causing-a-shift-towards-preventive-health-care/ monthly 0.6 https://www.lupin.com/media/perspectives/how-to-address-gender-disparities-in-diagnosis-and-treatment/ monthly 0.6 https://www.lupin.com/media/perspectives/indias-diabetes-crisis-comprehensive-strategies-for-prevention-and-early-intervention/ monthly 0.6 https://www.lupin.com/media/perspectives/indias-tuberculosis-endemic-in-the-covid-19-era-2/ monthly 0.6 https://www.lupin.com/media/perspectives/integrated-healthcare-solutions-that-puts-patients-first/ monthly 0.6 https://www.lupin.com/media/perspectives/international-day-of-action-for-womens-health-why-investing-in-womens-health-is-important/ monthly 0.6 https://www.lupin.com/media/perspectives/lupin-banks-on-complex-generics-speciality-products-to-sustain-growth-in-fy26-27/ monthly 0.6 https://www.lupin.com/media/perspectives/lupin-hosts-hon-ambassador-of-india-to-the-usa-taranjit-singh-sandhu/ monthly 0.6 https://www.lupin.com/media/perspectives/lupins-going-beyond-the-pill-to-grow-its-digital-therapeutics-arm/ monthly 0.6 https://www.lupin.com/media/perspectives/lupins-legacy-building-a-better-tomorrow/ monthly 0.6 https://www.lupin.com/media/perspectives/mr-ravindra-kumar-vice-president-and-head-lupin-diagnostics-in-an-interview-with-shardul-nautiyal-financial-express/ monthly 0.6 https://www.lupin.com/media/perspectives/navigating-the-future-trends-and-innovations-in-diagnostics/ monthly 0.6 https://www.lupin.com/media/perspectives/nilesh-gupta-business-today-digital-transformation-in-indian-pharma-industry-is-building-tomorrow-january-2025/ monthly 0.6 https://www.lupin.com/media/perspectives/patent-expiry-of-significant-number-of-biologics-by-2030-presents-huge-opportunities-for-biosimilars-players/ monthly 0.6 https://www.lupin.com/media/perspectives/patient-awareness-and-empowerment-the-key-to-liver-health/ monthly 0.6 https://www.lupin.com/media/perspectives/patient-centricity-must-drive-the-pharma-sector/ monthly 0.6 https://www.lupin.com/media/perspectives/pharma-needs-a-dose-of-sustainability/ monthly 0.6 https://www.lupin.com/media/perspectives/pharmas-next-frontier-legacy-systems-to-life-changing-innovations/ monthly 0.6 https://www.lupin.com/media/perspectives/predictions-2022-diagnostics-to-be-centrestage-of-healthcare/ monthly 0.6 https://www.lupin.com/media/perspectives/recalibrating-strategy/ monthly 0.6 https://www.lupin.com/media/perspectives/redefining-the-pharmaceutical-industrys-role-in-combating-climate-change/ monthly 0.6 https://www.lupin.com/media/perspectives/rethinking-and-reinventing-corporate-india/ monthly 0.6 https://www.lupin.com/media/perspectives/revolutionizing-cancer-care-a-call-for-accessibility-and-affordability-in-india/ monthly 0.6 https://www.lupin.com/media/perspectives/scalability-the-key-for-biosimilar-manufacturing/ monthly 0.6 https://www.lupin.com/media/perspectives/shift-in-customer-dynamics-fueling-future-forward-business-growth/ monthly 0.6 https://www.lupin.com/media/perspectives/small-steps-towards-better-heart-health-how-can-indias-young-avoid-heart-ailments/ monthly 0.6 https://www.lupin.com/media/perspectives/sourabh-agrawal-interview-campaign-india-jan-2025-featured-in-the-cmos-column-22-01-2025/ monthly 0.6 https://www.lupin.com/media/perspectives/spotlight-on-indian-pharmas-resilience-during-pandemic-times/ monthly 0.6 https://www.lupin.com/media/perspectives/start-them-young-the-importance-of-mental-health-awareness-among-adolescents/ monthly 0.6 https://www.lupin.com/media/perspectives/step-up-for-nash-livalert-to-confront-the-silent-threat-of-liver-diseases/ monthly 0.6 https://www.lupin.com/media/perspectives/strong-financial-planning-key-for-making-healthcare-accessible-roadmap-for-2024/ monthly 0.6 https://www.lupin.com/media/perspectives/the-3cs-to-solve-the-tb-conundrum/ monthly 0.6 https://www.lupin.com/media/perspectives/the-40-crore-ai-payoff-how-lupin-is-building-a-data-first-ai-ready-pharma-enterprise/ monthly 0.6 https://www.lupin.com/media/perspectives/the-battle-against-tb-needs-to-be-stepped-up/ monthly 0.6 https://www.lupin.com/media/perspectives/the-diabetes-epidemic-in-india-embracing-a-healthier-future/ monthly 0.6 https://www.lupin.com/media/perspectives/the-evolving-landscape-of-head-and-neck-cancer-care-in-india/ monthly 0.6 https://www.lupin.com/media/perspectives/the-rising-threat-of-liver-diseases-why-screening-matters/ monthly 0.6 https://www.lupin.com/media/perspectives/the-role-of-emerging-technologies-in-scaling-healthcare-through-digital-therapeutics/ monthly 0.6 https://www.lupin.com/media/perspectives/the-silent-crisis-young-adults-battling-heart-disease/ monthly 0.6 https://www.lupin.com/media/perspectives/the-silent-killer-meets-its-match-digital-therapeutics-in-hypertension-management/ monthly 0.6 https://www.lupin.com/media/perspectives/the-urgency-of-addressing-respiratory-diseases-disproportionate-impact-on-global-health/ monthly 0.6 https://www.lupin.com/media/perspectives/towards-a-cleaner-future-bringing-renewable-energy-and-green-chemistry-into-mainstream-pharma/ monthly 0.6 https://www.lupin.com/media/perspectives/towards-a-tb-free-india-2/ monthly 0.6 https://www.lupin.com/media/perspectives/transforming-heart-health-in-india-leveraging-integrated-affordable-care/ monthly 0.6 https://www.lupin.com/media/perspectives/trends-2025-redefining-the-pharma-supply-chain/ monthly 0.6 https://www.lupin.com/media/perspectives/understanding-and-managing-hypertension/ monthly 0.6 https://www.lupin.com/media/perspectives/uniting-against-head-neck-cancer/ monthly 0.6 https://www.lupin.com/media/perspectives/we-are-expanding-our-cdmo-capabilities-to-meet-the-next-wave-of-complex-therapies-starting-with-oncology/ monthly 0.6 https://www.lupin.com/media/perspectives/we-are-planning-to-expand-our-therapeutic-footprint-in-high-demand-disease-areas/ monthly 0.6 https://www.lupin.com/media/perspectives/why-gender-specific-approaches-to-cardiac-disease-are-vital/ monthly 0.6 https://www.lupin.com/media/perspectives/womens-heart-health-in-india-a-growing-concern/ monthly 0.6 https://www.lupin.com/media/perspectives/world-environment-day-why-a-collective-action-needed-to-navigate-the-environmental-impact/ monthly 0.6 https://www.lupin.com/media/perspectives/world-lung-day-2023-how-to-break-down-barriers-to-healthy-lungs/ monthly 0.6 https://www.lupin.com/media/press-releases/ monthly 0.6 https://www.lupin.com/media/press-releases/4qfy20-and-fy20-earnings-conference-call-on-29-may-2020/ monthly 0.6 https://www.lupin.com/media/press-releases/6-years-of-sustained-growth-lupin-net-profit-up-by-27-in-fy-2010-11/ monthly 0.6 https://www.lupin.com/media/press-releases/alliance-to-commercialize-generic-equivalent-of-fosrenol-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/american-academy-of-ophthalmology-and-lupin-collaborate-to-enhance-continuing-ophthalmic-medical-education-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/astellas-and-lupins-subsidiary-kyowa-enter-into-an-agreement/ monthly 0.6 https://www.lupin.com/media/press-releases/boehringer-ingelheim-india-and-lupin-expand-collaboration-for-co-marketing-of-two-oral-anti-diabetic-drugs/ monthly 0.6 https://www.lupin.com/media/press-releases/co-authored-article-by-dr-cyrus-karkaria-president-biotech-business-and-sanjay-tiwari-vice-president-rd-biotech-on-biotech-industry-propels-research-innovation-ethical-solutio/ monthly 0.6 https://www.lupin.com/media/press-releases/consistent-growth-net-sales-up-17-india-and-japan-drive-growth/ monthly 0.6 https://www.lupin.com/media/press-releases/consistent-growth-robust-profits-quarter-ii-results-fy-2013-14-net-sales-up-18-ebitda-up-42-net-profit-up-40/ monthly 0.6 https://www.lupin.com/media/press-releases/dr-desh-bandhu-gupta-aaips-award-2019-conferred-on-dr-umesh-gupta/ monthly 0.6 https://www.lupin.com/media/press-releases/dr-desh-bandhu-gupta-founder-and-chairman-of-lupin-passes-away/ monthly 0.6 https://www.lupin.com/media/press-releases/dr-kamal-k-sharma-to-join-lupin-as-managing-director/ monthly 0.6 https://www.lupin.com/media/press-releases/dr-vijay-kelkar-and-mr-r-a-shah-join-lupin-board/ monthly 0.6 https://www.lupin.com/media/press-releases/dsm-anti-infectives-india-and-lupin-enter-into-a-strategic-cooperation-for-cephalosporins/ monthly 0.6 https://www.lupin.com/media/press-releases/dst-and-lupin-join-hands-over-migraine-and-psoriasis-2/ monthly 0.6 https://www.lupin.com/media/press-releases/dst-and-lupin-join-hands-over-migraine-and-psoriasis/ monthly 0.6 https://www.lupin.com/media/press-releases/effrx-pharmaceuticals-signs-exclusive-licensing-and-distribution-agreement-with-lupin-for-commercialization-of-binosto-in-vietnam-philippines/ monthly 0.6 https://www.lupin.com/media/press-releases/eli-lilly-india-and-lupin-announce-strategic-collaboration-to-help-fight-the-battle-against-diabetes/ monthly 0.6 https://www.lupin.com/media/press-releases/ernst-young-announces-lupin-pharmaceuticals-inc-ceo-vinita-gupta-as-entrepreneur-of-the-year-maryland-060712/ monthly 0.6 https://www.lupin.com/media/press-releases/fiscal-year-2019-results/ monthly 0.6 https://www.lupin.com/media/press-releases/frances-ansm-completes-inspection-at-lupins-mandideep-facility-unit-1/ monthly 0.6 https://www.lupin.com/media/press-releases/governor-murphy-and-local-leaders-attend-ribbon-cutting-ceremony-marking-the-inauguration-of-lupins-new-corporate-offices-in-bridgewater/ monthly 0.6 https://www.lupin.com/media/press-releases/hdma-honors-lupin-with-diana-award-for-best-overall-generic-manufacturer/ monthly 0.6 https://www.lupin.com/media/press-releases/intimation-sent-to-the-bse-nse-in-connection-with-change-in-the-partnership-interest-of-the-company-in-abcd-technologies-llp/ monthly 0.6 https://www.lupin.com/media/press-releases/intimation-to-the-stock-exchange-on-lpi-gavis-settlement-2/ monthly 0.6 https://www.lupin.com/media/press-releases/intimation-to-the-stock-exchange-on-lpi-gavis-settlement/ monthly 0.6 https://www.lupin.com/media/press-releases/japans-pmda-completes-inspection-of-lupins-mandideep-facility-unit-2/ monthly 0.6 https://www.lupin.com/media/press-releases/japans-pmda-issues-gmp-certificate-to-lupins-unit-ii-mandideep-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/jeffrey-kindler-and-alfonso-zulueta-join-lupin-board-as-independent-directors/ monthly 0.6 https://www.lupin.com/media/press-releases/letter-to-the-exchange-on-intimation-on-it-security-2/ monthly 0.6 https://www.lupin.com/media/press-releases/letter-to-the-exchange-on-intimation-on-it-security/ monthly 0.6 https://www.lupin.com/media/press-releases/luforbec-200-6-beclometasone-200mcg-formoterol-6mcg-a-certified-carbon-neutral-inhaler-is-launched-in-the-uk-for-the-treatment-of-adult-asthma123/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-achieves-gmp-certification-from-tga-australia-for-dabhasa-api-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-achieves-significant-milestone-with-iso-14001-and-iso-45001-certification-across-all-its-indian-manufacturing-sites-rd-center-and-corporate-office/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-3-trademarks-from-boehringer-ingelheim-to-strengthen-diabetes-portfolio/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-biocom-in-russia/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-branded-product-portfolio-from-shionogi-in-japan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-brands-ondero-and-ondero-met-to-expand-diabetes-portfolio-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-five-brands-from-menarini/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-gavis-to-expand-us-generic-business/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-huminsulin-from-lilly-to-enhance-diabetes-portfolio/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-in-japan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-irom-pharmaceuticals-through-its-japanese-subsidiary/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-laboratorios-grin-s-a-de-c-v-mexico-specialty-ophthalmic-company-enters-the-latin-american-market/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-majority-stake-in-multicare-pharmaceuticals-philippines-inc/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-medquimica-in-brazi/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-nine-brands-of-medical-nutritional-institute-in-south-africa/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-southern-cross-pharma-in-australia/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-specialty-product-portfolio-in-germany/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-stake-in-generic-health-australia/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-symbiomix-therapeutics-llc/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-acquires-worldwide-rights-for-the-goanna-brand/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-agm-e-voting-notice/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-abbvie-announce-partnership-to-develop-and-commercialize-novel-oncology-drug-to-treat-hematological-cancers/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-amman-pharma-sign-exclusive-licensing-and-supply-agreement-for-ranibizumab-biosimilar/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-aptissen-announce-exclusive-distribution-agreement-of-synolis-va-for-canada/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-aspen-decide-not-to-pursue-their-mou-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-aspen-decide-not-to-pursue-their-mou/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-aspen-sign-tb-deal/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-avas-launch-namuscla-in-italy/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-axantia-enter-into-a-license-supply-and-technology-sharing-agreement-for-pegfilgrastim-in-the-middle-east-and-north-africa/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-biomm-enter-into-a-distribution-and-marketing-agreement-for-pegfilgrastim-in-brazil/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-birmingham-city-university-honour-graduates-of-masters-programme-in-advancing-diabetes-care/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-boehringer-ingelheim-announce-partnership-to-develop-and-commercialize-novel-oncology-drug-to-treat-kras-driven-cancers/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-boehringer-ingelheim-announce-strategic-co-marketing-agreement/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-celon-announce-strategic-development-and-licensing-agreement-for-generic-advair-diskusi/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-cornerstone-end-development-agreement/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-dafra-decide-not-to-pursue-their-mou/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-dksh-sign-an-exclusive-licensing-and-supply-agreement-to-market-five-biosimilar-candidates-in-the-philippines/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-eli-lilly-expand-partnership-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-european-association-of-urology-successfully-conclude-masterclass-best-of-eau19/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-exeltis-announce-reimbursement-approval-of-namuscla-in-spain-for-the-symptomatic-treatment-of-myotonia-in-adults-with-non-dystrophic-myotonic-ndm-disorders/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-fuji-sign-license-and-supply-agreement-for-commercialization-of-nextstellis-in-vietnam-and-philippines/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-honeywell-move-forward-jointly-with-plans-for-hfo-technology-in-inhalers/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-huons-sign-license-and-supply-agreement-for-commercialization-of-cyclosporine-ophthalmic-nanoemulsionin-mexico/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-ind-swift-launch-new-anti-diarrhoeal-drug/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-irom-enter-into-an-exclusive-licensing-agreement-for-denosumab-biosimilar-for-japan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-lilly-expand-partnership-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-mcgm-unite-to-launch-anti-tb-campaign-in-mumbai/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-medicis-enter-into-joint-development-agreement/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-monosol-rx-announce-licensing-agreement-for-multiple-pediatric-focused-products/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-mylan-announce-positive-european-medicines-agency-opinion-recommending-approval-of-nepexto-biosimilar-etanercept/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-mylan-launch-nepexto-biosimilar-etanercept-in-germany/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-mylan-partner-to-commercialize-enbrel-etanercept-biosimilar/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-mylan-receive-european-marketing-authorization-for-nepexto-biosimilar-etanercept/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-napcon-hosts-a-walkathon-a-step-towards-healthy-lungs-for-copd-awareness/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-natco-receive-approval-from-u-s-fda-for-bosentan-tablets-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-nichi-iko-announce-strategic-partnership-for-commercialization-of-biosimilar-etanercept-in-japan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-rotary-join-hands-to-combat-tuberculosis-in-mumbai/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-salix-announce-exclusive-distribution-agreement-for-canada-zaxine-relistor-and-other-gastroenterology-products/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-scope-sign-a-distribution-agreement-for-the-commercialization-of-optase-range-of-products-in-mexico/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-sino-universal-pharmaceuticals-sign-license-and-supply-agreement-for-tiotropium-dpi-in-china/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-slurrp-successfully-conclude-lupin-aptivate-achchi-bhookh-quiz/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-steincares-enter-into-license-and-supply-agreement-for-ranibizumab-in-latin-america/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-symbiotec-decide-not-to-pursue-their-mou/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-yabao-announce-strategic-partnership-in-china/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-yl-biologics-receives-pmda-approval-for-etanercept-biosimilar-in-japan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-yoshindos-jv-yl-biologics-announces-successful-outcome-of-global-phase-iii-study-for-etanercept-biosimilar-in-rheumatoid-arthritis/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-zentiva-sign-license-and-supply-agreement-for-commercializing-certolizumab/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-and-zydus-sign-licensing-agreement-for-co-marketing-saroglitazar-mg-a-critical-treatment-for-chronic-liver-diseases-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-achievement-of-key-milestone-for-its-phase-1-clinical-stage-malt-1-inhibitor-program/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-achievement-of-key-milestones-for-its-clinical-stage-mek-inhibitor-compound/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-acquisition-of-french-pharmaceutical-company-medisol/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-appointment-of-new-independent-director/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-closure-of-inspection-by-u-s-fda-at-its-nagpur-unit-1-facility-with-no-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-closure-of-inspection-by-u-s-fda-at-its-somerset-facility-with-no-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-closure-of-us-fda-audits-for-its-mandideep-and-aurangabad-facilities/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-closure-of-us-fda-inspection-at-its-injectable-facility-with-zero-483-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-completion-of-kyowa-divestiture-to-unison/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-completion-of-pharmacovigilance-inspection-by-the-u-s-fda-with-no-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-district-court-ruling-on-ramipril/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-executive-board-leadership-changes/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-executive-leadership-change-dr-fabrice-egros-to-assume-corporate-development-responsibilities-as-president-corporate-development-growth-markets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-favorable-ruling-for-generic-yaz-oral-contraceptive-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-fda-approval-of-supplemental-new-drug-application-for-solosec-secnidazole-for-the-treatment-of-trichomoniasis/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-fda-approval-of-supplemental-new-drug-application-for-solosec-secnidazole-in-adolescents-for-both-the-treatment-of-bacterial-vaginosis-in-females-and-trichomoniasis/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-fda-filing-acceptance-of-supplemental-new-drug-application-for-solosec/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-final-fda-approval-for-nabumetone-tablets-500-mg-and-750-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-final-fda-approval-for-suprax-cefixime-chewable-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-final-fda-approval-of-cefdinir-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-final-fda-approval-of-generic-hyzaar-and-cozaar/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-fiscal-year-2018-results-board-recommends-dividend-of-250/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-health-canada-approval-of-tiotropium-bromide-inhalation-powder-for-treatment-of-copd/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-launch-of-generic-keppra-xr-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-launch-of-generic-levaquin-tablets-for-the-us-market/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-launch-of-orphan-drug-namuscla-in-germany-and-the-uk-for-the-treatment-of-myotonia-in-non-dystrophic-myotonic-disorders/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-licensing-arrangement-with-neuclone-inks-strategic-deal-with-neuclone-for-cell-line-technology/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-licensing-deal-for-ranibizumab-biosimilar/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-litigation-settlement-with-forest-for-memantine-tablets-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-litigation-settlement-with-forest-for-memantine-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-litigation-settlement-with-schering-plough-corporation-for-desloratadine/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-litigation-settlement-with-wyeth-for-venlafaxine-extended-release-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-new-center-of-excellence-for-inhalation-research-in-florida/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-patent-license-agreement-with-abbott/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-plans-to-build-a-new-state-of-the-art-manufacturing-facility-in-coral-springs-florida/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-positive-topline-results-from-its-phase-3-study-of-single-dose-solosec/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp3693-sting-agonist-at-the-esmo-congress-2025/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-resolution-of-usfda-warning-letter-for-its-goa-and-pithampur-facilities/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-settlement-with-santarus-and-depomed-for-glumetza-patent-litigation/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-settlement-with-warner-chilcott-of-loestrin-24-fe-and-femcon-fe-patent-litigations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-strategic-alliance-for-emerging-markets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-successful-completion-of-phase-3-trials-for-lucentis-biosimilar/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-successful-completion-of-uk-mhra-inspection-of-its-pithampur-facilities/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-tentative-fda-approval-for-metformin-hydrochloride-extended-release-tablets-500-mg-and-1000-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-tentative-fda-approval-for-pregabalin-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-the-acquisition-of-renascience-in-the-united-kingdom/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-the-launch-of-cetuximab/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-the-launch-of-its-diagnostics-business/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-tie-up-with-european-association-of-urology-eau/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-u-s-fda-acceptance-for-pegfilgrastim-biosimilar-application/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-u-s-fda-approval-of-its-first-oral-contraceptive/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-announces-uk-mhra-approval-of-lutio-tiotropium-bromide-inhalation-powder-for-treatment-of-copd/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-abdelaziz-toumi-as-ceo-of-its-api-cdmo-subsidiary/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-alok-sonig-as-ceo-us-generics-and-global-head-generics-rd-biosimilars/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-christoph-funke-as-chief-technical-operations-officer/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-claus-jepsen-as-president-global-specialty/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-diana-amador-toro-as-senior-vice-president-global-compliance/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-divakar-kaza-as-president-human-resources/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-dr-kamal-k-sharma-as-advisor-to-the-company/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-dr-kurt-nielsen-as-president-of-lupin-somerset/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-dr-maurice-chagnaud-as-president-europe-head-of-inhalation-strategy/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-dr-ranjana-pathak-as-chief-quality-officer/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-fabrice-egros-as-president-of-its-asia-pacific-business/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-indrajit-banerjee-as-president-finance-and-planning/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-j-alan-butcher-as-chief-corporate-development-officer/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-jim-loerop-as-chief-corporate-development-officer/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-johnny-mikell-as-global-head-of-quality/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-jon-stelzmiller-as-president-of-us-specialtybusiness/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-martin-mercer-as-president-of-its-latin-american-business/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-mrs-manju-deshbandhu-gupta-as-chairman/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-ms-christine-mundkur-as-an-independent-director/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-new-nce-research-head/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-new-president-for-asia-pacificlatin-america/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-nicholas-hart-as-president-specialty-for-us-business/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-paul-mcgarty-as-president-for-lupin-pharmaceuticals-inc/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-rakesh-bhardwaj-as-chief-information-officer/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-ramesh-swaminathan-as-chief-financial-officer-and-head-corporate-affairs/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-ramesh-swaminathan-as-president-finance-planning/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-spiro-gavaris-as-president-of-u-s-generics-business/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-theresa-stevens-as-chief-corporate-development-officer/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-thierry-volle-as-president-europe-middle-east-africa-emeapress-release-use/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-yashwant-mahadik-as-president-global-hr/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-appoints-yugesh-goutam-as-president-global-hr/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-aspen-sign-joint-venture/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-awarded-ecovadis-silver-medal-for-sustainability-excellence-ranks-among-the-top-15-globally/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-banks-on-complex-generics-speciality-products-to-sustain-growth-in-fy26-27/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-bio-research-centre-completes-u-s-fda-inspection-with-no-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-bioresearch-center-receives-zero-observations-from-u-s-fda-after-successful-inspection-and-assessment/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-bioresearch-centre-completes-fifth-successful-u-s-fda-inspection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-carves-out-lupinlife-consumer-healthcare/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-collaborates-with-mark-cuban-cost-plus-drug-company-and-copd-foundation-to-expand-access-to-medication-for-copd-patients/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-completes-acquisition-of-brands-from-anglo-french/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-completes-acquisition-of-two-brands-from-sanofiin-europe-and-canada/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-completes-acquistion-of-pharma-dynamics-south-africa/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-completes-its-acquisition-of-gavis/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-confirms-security-incident-days-after-cyber-attack-at-dr-reddys/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-contributes-inr-21-crores-towards-covid-19-relief-efforts/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-cranks-up-the-rd-engine/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-diagnostics-achieves-nabl-accreditation-for-all-greenfield-labs/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-diagnostics-expands-its-footprint-in-central-india-launches-regional-reference-laboratory-in-indore/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-diagnostics-expands-presence-in-south-india-with-new-regional-reference-laboratory-in-chennai/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-diagnostics-expands-presence-in-south-india-with-new-regional-reference-laboratory-in-hyderabad/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-diagnostics-launches-its-first-reference-laboratory-in-ranchi/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-diagnostics-launches-its-first-regional-reference-laboratory-in-patna/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-diagnostics-launches-regional-reference-laboratory-in-bengaluru-strengthening-presence-in-south-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-diagnostics-launches-satellite-laboratory-in-vijayawada/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-digital-health-and-the-american-college-of-cardiology-announce-first-of-its-kind-collaboration-to-revolutionize-in-home-cardiovascular-care-in-india-with-digital-therapeutics/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-digital-health-introduces-comprehensive-post-procedure-home-based-care-guide-in-collaboration-with-the-american-college-of-cardiology/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-digital-health-introduces-digital-therapeutics-certificate-for-cardiologists-in-india-in-collaboration-with-the-american-college-of-cardiology/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-digital-health-launches-first-of-its-kind-digital-heart-failure-clinic-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-digital-health-launches-vitalyfe/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-digital-health-partners-with-medicover-hospitals-for-comprehensive-post-discharge-cardiac-care/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-digital-health-unveils-results-of-indias-first-digital-therapeutics-study-with-acs-patients/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-digital-healths-lyfe-platform-receives-class-c-medical-device-license-from-cdsco/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-divests-kyowa-criticare-to-neopharma-group/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-donates-oxygen-generation-plants-in-maharashtra-madhya-pradesh-gujarat-to-aid-covid-19-relief-efforts/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-dermatology-segment-in-brazil-with-launch-of-lupin-high-end-skin-science/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-into-a-co-operation-agreement-with-kyowa-for-japanese-market/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-into-a-marketing-alliance-with-forest-laboratories-inc-for-aerochamber-plus-brand-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-into-a-non-exclusive-patent-licensing-agreement-with-takeda-to-commercialize-vonoprazan-a-novel-gastrointestinal-drug-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-into-agreement-to-divest-its-stake-in-kyowa-to-unison/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-into-collaboration-to-promote-zymar-to-pediatricians-in-the-u-s/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-into-licensing-agreement-with-alvion-to-market-cardiometabolic-drugs-in-the-southeast-asia-region/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-into-marketing-alliance-with-ascend-therapeutics-for-suprax-400-mg-tablets-in-the-u-s/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-into-voluntary-licensing-agreement-with-lilly-to-expand-access-for-covid-19-treatment-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-enters-the-sp-global-sustainability-yearbook-2024/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-establishes-a-new-global-standard-in-sustainable-pharma-with-an-sp-global-esg-score-of-91/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-expands-branded-play-announces-acquisition-of-exclusive-us-rights-to-alinia-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-expands-branded-play-announces-acquisition-of-us-rights-to-antara/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-expands-branded-play-announces-acquisition-of-worldwide-rights-for-its-first-nda-allernaze/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-expands-us-pediatric-brands-portfolio-inks-strategic-agreement-to-promote-locoid-lotion-to-us-pediatricians/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-extends-jan-kovid-helpline-for-bhopal-and-indore-citizens/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-facilitates-the-best-of-acg-in-association-with-american-college-of-gastroenterology/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-files-inda-for-anti-psoriasis/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-finalizes-patent-sale-agreement-with-servier/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-forays-into-the-otc-segment-with-softovac/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-foundation-flags-off-mobile-medical-van-in-palghar-to-strengthen-non-communicable-disease-care/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-foundation-is-transforming-communities-and-lives-in-bharatpur-and-alwar/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-foundation-organizes-state-level-workshop-to-enhance-healthcare-systems-in-rajasthan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-foundation-strengthens-lives-program-with-its-first-mobile-medical-van-flag-off-by-health-minister-government-of-rajasthan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-foundation-trains-7000-plus-farmers-at-the-natural-farming-workshop-in-bharatpur/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-foundation-wins-award-for-excellence-in-corporate-social-responsibility-at-india-pharma-awards-2019/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-foundation-wins-idma-corporate-citizen-award-2019/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-05-net-sales-up-4-at-rs-11611-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2003-04-revenue-up-22-at-rs-12-3-bn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2006-07-q1-sales-up-by-33-at-rs-4-9-bn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2006-07-q2-net-profit-up-by-29-at-rs-583-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2006-07-q3-net-profit-up-by-27-at-rs-560-mn-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2006-07-q3-net-profit-up-by-27-at-rs-560-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2007-08-consolidated-net-profit-up-32-to-rs-4083-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2007-08-q1-net-profit-up-55-to-rs-784-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2007-08-q2-consolidated-net-profit-up-46-to-rs-756-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy-2009-10-consolidated-net-profits-up-36-to-rs-6816-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy2002-03-net-sales-up-19-at-rs-10-3-bn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy2020-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy2022-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-fy2025-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-dcgi-approval-to-conduct-phase-iii-clinical-trials-for-migraine-nce/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-eir-from-us-fda-for-its-ankleshwar-manufacturing-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-mhra-approval-for-lisinopril-in-uk/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-new-pharmaceutical-research-head/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-tentative-us-fda-approval-for-sertraline-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-tentative-us-fda-approval-for-sertraline/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-tentative-us-fda-approval-for-trandolapril/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-us-fda-approval-for-ceftriaxone-10gm-vials/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-us-fda-approval-for-lisinopril-hctz-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-usfda-approval-for-cefdinir-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-gets-usfda-approval-for-meloxicam/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-has-entered-into-an-agreement-with-gsk-philippines/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-hosts-second-edition-of-aptivate-champion-run-for-kids/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-in-alliance-with-natco-receives-fda-approval-for-bosentan-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-in-alliance-with-natco-receives-fda-approval-for-imatinib-mesylate-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-in-alliance-with-natco-to-commercialize-generic-equivalent-of-tykerb-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-in-equity-partnership-with-pharma-dynamics-south-africa/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-inks-strategic-joint-venture-agreement-with-yoshindo-inc/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-joins-hands-with-italfarmaco-to-launch-lupenox-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-additional-strengths-of-generic-lotrel-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-adhero-first-of-its-kind-connected-smart-device-in-india-to-support-treatment-of-respiratory-disease/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-aptivate-achi-bhookh-fest-in-mumbai-and-suburbs/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-aptivate-champion-run-for-kids-promotingwell-being-and-good-eating-habits/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-atharv-ability-state-of-the-art-multi-disciplinary-neuro-rehabilitation-center-in-mumbai/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-atorvastatin-calcium-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-for-celebrex-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-of-femcon-fe/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-alinia/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-antara-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-apriso/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-brovana-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-duexis-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-pennsaid-2-w-w-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-ravicti-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-authorized-generic-version-of-vimovo/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-basugine/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-betamethasone-dipropionate-ointment-usp-augmented/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-bosentan-tablets-for-oral-suspension-in-the-united-states-with-180-day-exclusivity/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-branded-finished-dosage-in-the-us-sets-up-pediatric-sales-force/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-bromfenac-ophthalmic-solution-0-075-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-bromfenac-ophthalmic-solution-0-07in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-budesonide-inhalation-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-bumetanide-injection-usp-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-ceftriaxone-vials-in-the-us-market/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-clobazam-oral-suspension-2-5mg-ml/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-clobazam-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-clomipramine-hydrochloride-capsules-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-corcal-bone-and-beauty-supplement/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-cyanocobalamin-nasal-spray-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-darunavir-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-desvenlafaxine-extended-release-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-diazepam-rectal-gel-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-divalproex-sodium-er-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-doxercalciferol-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-doxorubicin-hydrochloride-liposome-injection-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-doxycycline-for-injection-usp-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-droxidopa-capsules-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-emtricitabine-and-tenofovir-disoproxil-fumarate-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-eslicarbazepine-acetate-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-ethacrynic-acid-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-favipiravir-drug-covihalt-for-treatment-of-mild-to-moderate-covid-19-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-favipiravir-drug-covihalt-for-treatment-of-mild-to-moderate-covid-19/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-first-ever-duloxetine-40mg-delayed-release-capsules-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-first-generic-of-pred-forte-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-first-generic-version-of-oracea-doxycycline-capsules-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-fluocinonide-ointment-usp-0-05/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-fluoxetine-tablets-usp-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-fluoxetine-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-formoterol-fumarate-inhalation-solution-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-fosaprepitant-for-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-ganirelix-acetate-injection-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-aciphex-delayed-release-tablets-20-mg-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-acticlate-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-activella-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-ancobon-capsules-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-aricept-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-atovaquone-oral-suspension-usp-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-axiron-topical-solution-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-benicar-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-cipro-for-oral-suspension-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-clobetasol-propionate-cream-usp-0-05-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-clobetasol-propionate-ointment-usp-0-05-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-clobex-lotion-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-clobex-spray-0-05-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-combivir-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-cymbalta-delayed-release-capsules-20-mg-30-mg-and-60-mg-strengths-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-desoximetasone-topical-spray-0-25-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-diovan-hct-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-diovan-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-drospirenone-ethinyl-estradiol-levomefolate-calcium-tablets-and-levomefolate-calcium-tablets-3-mg-0-02-mg-0-451-mg-and-0-451-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-epzicom-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-exforge-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-femhrt-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-fosrenol-chewable-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-glumetza-hci-er-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-intermezzo-sublingual-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-kapvay-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-kcl-for-oral-solution-usp-20-meq/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-levothyroxine-sodium-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-lodosyn-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-methylergonovine-maleate-tabs-usp-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-minastrin-24-fe-chewable-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-minocycline-hydrochloride-er-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-ms-contin-er-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-namenda-xr-capsules-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-niaspan-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-norco-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-nystatin-and-triamcinolone-acetonide-cream-usp-100000-units-gm-0-1/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-ortho-cyclen-28-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-ortho-tri-cyclen-lo-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-ortho-tri-cyclen-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-paxil-cr-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-phoslo-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-potassium-chloride-oral-solution-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-pristiq-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-safyral-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-seasonale-tablets-receives-fda-approval/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-seroquel-xr-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-silodosin-capsules-4mg-and-8mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-suprep-bowel-prep-kit-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-tamiflu-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-temovate-clobetasol-propionate-scalp-application-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-tetrabenazine-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-tobramycin-inhalation-solution-usp-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-topicort-lp-emollient-cream-and-topicort-cream-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-tricor-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-trilipix-delayed-release-capsules-45-mg-135-mg-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-trizivir-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-vfend-tablets-and-vfend-oral-suspension-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-vibra-tabs-tablet-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-vigamox-ophthalmic-solution-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-wellbutrin-xl-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-generic-zymaxid-ophthalmic-solution-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-glucagon-for-injection-usp-1mg-vial-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-herbal-business/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-humrahi-unique-patient-support-program-for-diabetes-management/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-hyalgan-in-india-marks-foray-into-the-orthopaedics-segment/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-hydrocodone-bitartrate-and-acetaminophen-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-hydrocortisone-valerate-cream/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-imatinib-mesylate-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-indias-first-chatbot-for-patients/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-ipratropium-bromide-nasal-solution-nasal-spray-0-03-and-0-06-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-its-first-reference-laboratory-in-east-india-establishing-its-diagnostics-business-in-kolkata/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-its-oral-contraceptive-dayseetm-tablets-in-the-us-market-generic-of-seasonique-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-its-regional-reference-laboratory-in-guwahati-assam/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-jan-kovid-helpline-for-mumbai-citizens/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-jeet-a-patient-support-program-to-raise-awareness-of-cardiovascular-disease-among-patients/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-lapatinib-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-leflunomide-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-liraglutide-injection-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-loteprednol-etabonate-ophthalmic-suspension-0-5-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-luforbec-100-6-for-adult-asthma-and-copd-treatment-in-germany/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-luforbec-100-6-µg-pmdi-first-branded-generic-alternative-to-fostair-100-6-µg-pmdi-for-treatment-of-asthma-copd-in-the-uk/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-lurasidone-hydrochloride-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-lyfe-its-digital-therapeutic-solution-for-holistic-heart-care/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-merzee-capsules-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-minzoya-tm-levonorgestrel-and-ethinyl-estradiol-tablets-usp-and-ferrous-bisglycinate-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-mirabegron-extended-release-tablets-in-the-united-states-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-mirabegron-extended-release-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-molnupiravir-under-the-brand-name-molnulup-for-the-treatment-of-covid-19-in-adults-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-moxifloxacin-ophthalmic-solution-usp-0-5/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-mycophenolate-mofetil-capsules-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-mycophenolate-mofetil-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-mycophenolic-acid-delayed-release-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-novel-cholesterol-fighter-ezedoc-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-novel-cholesterol-fighter-ezedoc/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-novel-fixed-dose-triple-drug-combination-difizma-dpi-to-treat-inadequately-controlled-asthma/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-novel-injectable-iron-formulation-under-brand-names/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-paliperidone-extended-release-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-penicillamine-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-posaconazole-delayed-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-propranolol-long-acting-capsules-to-improve-heart-health-in-canada/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-prucalopride-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-risperidone-long-acting-injectable-with-180-day-cgt-exclusivity-in-the-u-s-the-first-product-from-its-proprietary-long-acting-injectable-platform-precisionsphere/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-rivaroxaban-for-oral-suspension-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-rivaroxaban-tablets-usp-2-5mg-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-rocuronium-bromide-injection-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-rufinamide-oral-suspension-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-rufinamide-tablets-usp-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-rymti-biosimilar-etanercept-in-canada/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-sacubitril-and-valsartan-combination-drug-for-heart-failure-patients/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-sciflix-a-mobile-friendly-learning-platform-for-post-graduate-students-specializing-in-pulmonology/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-second-edition-of-aptivate-champion-run-for-kids-promoting-childrens-well-being-through-fitness-and-nutrition/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-sevelamer-hydrochloride-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-sildenafil-for-oral-suspension-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-sildenafil-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-softovac-liquifibre-a-first-of-its-kind-liquid-fibre/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-solosec-secnidazole-2g-oral-granules-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-suprax-400-mg-tablets-in-the-us/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-tacrolimus-capsules-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-tadalafil-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-tavaborole-topical-solution-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-testosterone-gel/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-thiamine-hydrochloride-injection-usp-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-tiotropium-dry-powder-inhaler-for-the-treatment-of-copd-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-tolvaptan-tablets-in-the-u-s-with-180-day-exclusivity/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-turqoznorgestrel-and-ethinyl-estradiol-tablets-uspin-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-varenicline-tablets-in-the-united-states/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-worlds-first-fixed-dose-triple-combination-drug-vilfuro-g-for-copd-management-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-zaxine-in-canada/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launches-zileuton-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launchesgeneric-geodon-capsules-receives-final-fda-approval-for-its-generic-geodon-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-launchesgeneric-seroquel-tablets-receives-final-fda-approval-for-its-generic-seroquel-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-lctl-divestment/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-licenses-us-rights-for-proprietary-bioadhesive-technology-for-rifaximin-to-salix-pharmaceuticals/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-life-announces-association-with-vikram-vedha-as-official-energy-partner-with-its-be-one-health-and-wellness-supplement/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-limited-places-us-100-million-foreign-currency-convertible-bonds/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-limited-quarter-i-results-fy2016/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-limited-quarter-ii-results-fy2016/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-limited-quarter-iii-results-fy2016/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-makes-a-hearty-entry-into-guinness-world-records-creates-awareness-on-monitoring-heart-rate-as-an-indicator-of-overall-health/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-makes-an-acquisition-in-germany/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-manufacturing-solutions-unveils-dedicated-oncology-block-at-vizag-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-named-amongst-aon-best-employers-india-2016/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-net-profit-up-38-q3-fy-2009-10/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-net-profit-up-77-at-rs-400-mn-net-sales-up-10-at-rs-2629-mndebt-equity-ratio-improves-to-0-851/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-net-profit-up-by-25-in-q1-fy-2009-10-outpacing-and-outperforming-markets-globally/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-net-profit-up-by-34-in-q2-fy-2010-11-robust-growth-strong-profits/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-net-profit-up-by-39-in-q3-fy-2010-11-sustained-growth-strong-profits/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-net-profit-up-by-40-in-q1-fy-2010-11-consistent-growth-strong-profits/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-net-sales-up-10-at-rs-2796-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-neurosciences-announces-positive-chmp-opinion-for-namuscla/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-partners-with-global-agencies-to-increase-patient-access-to-tuberculosis-prevention-treatment/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-partners-with-ttp-plc-uk-for-soft-mist-inhalation-technology-platform/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-pharma-canada-announces-partnership-with-endoceutics-for-the-commercialization-of-intrarosa/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-pharmaceuticals-inc-and-cornerstone-biopharma-inc-enter-co-promotion-agreement-for-suprax/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-pharmaceuticals-inc-issues-voluntary-recall-of-ceftriaxone-for-injection-usp-250mg-500mg-1g-and-2g/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-pr-lupin-launches-inspirachamber-anti-static-valved-holding-chamber_-expands-us-brands-portfolio/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-presents-phase-3-data-for-solosec-secnidazole-demonstrating-significant-response-rate-in-female-patients-with-trichomoniasis/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-promoters-newbridge-call-off-discussions/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q1-fy-2003-04-net-profit-up-38-at-rs-280-6-mn-sales-up-23-at-rs-2769-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q1-fy03-sales-at-rs-2514-million-up-8-net-up-26-at-rs-203-million/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q1-fy2023-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q1-fy2024-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q1-fy2025-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q1-fy2026-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2-fy-08-09-strong-performance-strategic-growth/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2-fy-2003-04-net-profit-before-extraordinary-items-at-rs-518-mnup-86-sales-up-36-at-rs-3609-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2-fy2023-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2-fy2024-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2-fy2025-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2-fy2026-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2-net-profit-up-39/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2-sales-up-23-at-rs-2985-mn-profit-before-tax-up-35-at-rs-353-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q2fy06-net-profit-soars-158-to-rs-452-million/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q3-fy-08-09-strong-growth-consistent-performance/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q3-fy0708-consolidated-net-profit-up-192-to-rs-1809-mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q3-fy2020-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q3-fy2023-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q3-fy2024-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q3-fy2025-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q3-sales-up-19-at-rs-2868-mn-net-profit-up-23-at-rs-227mn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q4-fy-2008-09-results-consistent-performance-solid-growth/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q4-fy2021-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q4-fy2023-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-q4-fy2024-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-1-fy2021-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-3-fy2022-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-i-fy-2020-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-i-fy2022-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy-2020-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy2018-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy2019-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy2021-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-ii-fy2022-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-iii-fy2018-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-iii-fy2019-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-iii-fy2021-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-quarter-iii-results-fy201/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-raises-awareness-about-mental-health-by-partnering-with-singer-shaan-to-relaunch-the-iconic-song-tanha-dil-tanha-safar/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-ranbaxy-sign-tb-deal/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-a-leadership-rating-from-cdp-in-two-categories-climate-change-and-water-security/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-acotiamide-tablets-to-treat-functional-dyspepsia/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-albendazole-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-bepotastine-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-betamethasone-dipropionate-ointment-usp-augmented/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-colesevelam-hydrochloride-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-conducting-phase-ii-trials-for-lll-3348-desoris/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-dimethyl-fumarate-delayed-release-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-droxidopa-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-generic-albuterol-sulphate-mdi/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-leflunomide-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-meloxicam-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-rufinamide-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-sevelamer-carbonate-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-sulfamethoxazole-and-trimethoprim-oral-suspension-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-tavaborole-topical-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-for-trientine-hydrochloride-capsules-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-tga-australia-for-tiotropium-dry-powder-for-inhaler-for-treatment-of-copd/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-abacavir-dolutegravir-and-lamivudine-tablets-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-allopurinol-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-arformoterol-tartrate-inhalation-solution15-mcg-base-2-ml/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-aripiprazole-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-azilsartan-medoxomil-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-brimonidine-tartrate-ophthalmic-solution-0-1/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-brivaracetam-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-bromfenac-ophthalmic-solution-0-07/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-bromfenac-ophthalmic-solution-0-075/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-bromfenac-ophthalmic-solution-0-09/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-bumetanide-injection-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-chlorpromazine-hydrochloride-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-cyanocobalamin-nasal-spray/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-darunavir-tablets-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-darunavir-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-desvenlafaxine-extended-release-tablets-25-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-diazepam-rectal-gel/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-diclofenac-sodium-topical-solution-usp-2-w-w/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-doxycycline-for-injection-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-doxycycline-hyclate-delayed-release-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-dronedarone-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-efinaconazole-topical-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-emtricitabine-and-tenofovir-alafenamide-tablets-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-emtricitabine-and-tenofovir-alafenamide-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-eslicarbazepine-acetate-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-febuxostat-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-fesoterodine-fumarate-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-fluconazole-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-fluocinolone-acetonide-body-oil/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-fluocinolone-acetonide-topical-oil/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-formoterol-fumarate-inhalation-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-ganirelix-acetate-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-iloperidone-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-ipratropium-bromide-nasal-solution-nasal-spray-0-03/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-ipratropium-bromide-nasal-solution-nasal-spray-0-06/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-lenalidomide-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-gel/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-suspension-0-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-suspension-0-5/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-meclizine-hydrochloride-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-metoprolol-succinate-extended-release-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-midostaurin-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-minzoya-tm-levonorgestrel-and-ethinyl-estradiol-tablets-usp-and-ferrous-bisglycinate-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-mirabegron-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-mixed-salts-of-a-single-entity-amphetamine-extended-release-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-obeticholic-acid-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-paliperidone-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-pirfenidone-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-pirfenidone-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-pitavastatin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-prasugrel-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-prednisolone-acetate-ophthalmic-suspension-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-pregabalin-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-propranolol-hydrochloride-extended-release-capsules-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-prucalopride-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-raltegravir-tablets-usp-600-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-rivaroxaban-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-rivaroxaban-tablets-usp-10-mg-15-mg-and-20-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-rufinamide-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-sevelamer-carbonate-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-sildenafil-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-tenofovir-alafenamide-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-tiotropium-dry-powder-inhaler/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-tolvaptan-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-topiramate-extended-release-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-travoprost-ophthalmic-solution-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-valbenazine-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-varenicline-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-vigabatrin-for-oral-solution-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-us-fda-for-brexpiprazole-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-us-fda-for-glycopyrrolate-injection-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-approval-from-us-fda-for-turqoz-norgestrel-and-ethinyl-estradiol-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-best-new-manufacturer-of-the-year-award-fromamerisourcebergen/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-dcgi-approval-to-conduct-combined-phase-iib-iii-clinical-trials-for-its-herbal-psoriasis-nce/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-dcgi-approval-to-conduct-phase-ii-clinical-trials-for-psoriasis-nce/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-for-pharmacovigilance-inspection-from-the-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-aurangabad-csn-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-aurangabad-manufacturing-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-dabhasa-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-mandideep-unit-2-manufacturing-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-nagpur-unit-1-manufacturing-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-pithampur-unit-1-facility-with-vai-classification/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-pithampur-unit-2-manufacturing-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-pithampur-unit-3-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-somerset-manufacturing-facility-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-u-s-fda-for-its-somerset-manufacturing-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-aurangabad-april-2017-inspection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-goa-july-2015-inspection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-goa-march-2016-inspection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-its-api-manufacturing-facility-in-vizag/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-its-injectable-facility-in-nagpur-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-eir-from-us-fda-for-its-injectable-facility-in-nagpur/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-atorvastatin-calcium-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-azacitidine-for-injection-100-mg-single-dose-vial/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-budesonide-inhalation-suspension-0-5-mg-2-ml/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-clobazam-oral-suspension-2-5-mg-ml/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-clomipramine-hcl-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-decitabine-for-injection-50-mg-vial-single-dose-vial/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-doxercalciferol-injection-4-mcg-2-ml-2-mcg-ml-multi-dose-vials/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-famotidine-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-fenofibrate-tablets-54-mg-and-160-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-fluocinonide-topical-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-fluoxetine-tablets-usp-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-fluoxetine-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-acticlate-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-activella-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-actos-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-ambien-cr-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-ancobon-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-aricept-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-atovaquone-oral-solution-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-avapro-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-axiron-topical-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-benicar-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-celebrex-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-clobex-lotion/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-clobex-spray-0-05/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-corgard-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-crestor-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-dovonex-scalp-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-drospirenone-ethinyl-estradiol/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-epivir-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-evoxac-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-flagyl-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-gabapentin-tablets-usp-600-mg-and-800-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-generes-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-generess-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-hydrocortisone-butyrate-lotion-0-1/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-hydroxychloroquine-sulfate-tablets-usp-200-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-kapvay-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-keppra-oral-solution-100-mg-ml/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-klor-con-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-lexapro-tablets-e-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-lidex-ointment/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-lodosyn-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-loestrin24-fe-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-monodox-capsules-and-cipro-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-mycobutin-capsules-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-mycobutin-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-namenda-xr-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-nitrofurantoin-capsules-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-norco-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-nuvigil-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-ortho-cyclen-28-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-paxil-cr-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-percocet-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-potassium-chloride-oral-solution-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-prilosec-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-ranexa-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-rifadin-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-roxicodone-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-safyral-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-seroquel-xr-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-solodyn-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-suprep-bowel-prep-kit/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-tamiflu-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-tamiflu-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-temovate-cream-0-05/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-temovate-ointment-0-05/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-tobi-inhalation-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-topicort-lp-emollient-cream-0-05-and-topicort-cream-0-25/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-topicort-ointment-0-05/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-topicort-topical-spray-0-25/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-triamcinolone-acetonide-ointment-usp-0-1/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-trizivir-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-vancocin-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-vibra-tabs-tablet/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-wellbutrin-xl-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-xenazine-tablets-12-5-mg-and-25-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-generic-zyvox-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-hydrocodone-bitartrate-and-acetaminophen-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-imipramine-pamoate-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-its-new-drug-application-for-antara-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-its-oral-contraceptive-kurvelo-tablets-the-generic-of-nordette-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-its-oral-contraceptive-pirmella-7-7-7-and-pirmella-1-35-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-its-oral-contraceptive-vyfemlatm-tablets-generic-of-ovcon-35-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-kcl-for-oral-solution-20-meq/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-lamotrigine-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-levothyroxine-sodium-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-lurasidone-hydrochloride-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-methylprednisolone-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-new-drug-application-for-suprax-oral-suspension-500-mg-5ml/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-nikita-pitavastatin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-potassium-chloride-extended-release-capsules-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-potassium-chloride-extended-release-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-sildenafil-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-suprax-cefixime-capsules-400-mg-nda-approval-to-add-to-growing-suprax-franchise/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-tadalafil-tablets-usp-20-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-tadalafil-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-testosterone-gel/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approval-for-triamcinolone-acetonide-cream/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approvals-for-generic-loestrin-fe-1-20-and-loestrin1-5-30-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-approvals-for-generic-vfend-tablets-50mg-200mg-vfend-oral-suspension-40-mg-ml/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-fda-tentative-approval-for-eszopiclone-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-final-approval-for-quinapril-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-final-approval-to-market-generic-ultram-er/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-final-fda-approval-for-generic-loseasonique-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-final-fda-approval-for-trandolapril/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-health-canada-approval-for-biosimilar-pegfilgrastim/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-health-canada-approval-for-propranolol-hydrochloride-er-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-health-canada-approval-for-rymti-biosimilar-etanercept/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-ind-approvals-for-anti-tb-and-anti-psoriasis-molecules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-inda-approval-for-psoriasis-oral-treatment-april-22-2004/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-international-sustainability-rating-standard-isrs-certification-first-pharmaceutical-company-globally-to-adopt-isrs-8th-edition-standard/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-international-sustainability-rating-system-isrs-certification-8th-edition/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-sanda-approval-from-u-s-fda-for-levothyroxine-sodium-tablets-usp-to-be-considered-ab-rated-to-reference-listed-drug-unithroid/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-sanda-approval-from-us-fda-for-levothyroxine-sodium-tablets-usp-ab-rating-to-reference-listed-drug-levoxyllupin-receives-approval-for-droxidopa-capsules-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-arformoterol-tartrate-inhalation-solution-15-mcg-base-2-ml/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-efinaconazole-topical-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-empagliflozin-and-linagliptin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-empagliflozin-and-metformin-hydrochloride-er-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-empagliflozin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-benicar-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-cymbalta-delayed-release-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-epzicom-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-giazo-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-glumetza-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-lexiva-tablets-700-mg-from-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-livalo-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-paxil-cr-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-prezista-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-rapaflo-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-zithromax-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-for-generic-zorvolex-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-abacavir-dolutegravir-and-lamivudine-tablets-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-amifampridine-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-apalutamide-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-azilsartan-medoxomil-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-bictegravir-emtricitabine-and-tenofovir-alafenamide-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-brexpiprazole-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-brimonidine-tartrate-ophthalmic-solution-0-025-otc/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-canagliflozin-and-metformin-hydrochloride-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-canagliflozin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dapagliflozin-and-saxagliptin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dapagliflozin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-darunavir-cobicistat-emtricitabine-and-tenofovir-alafenamide-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dasatinib-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-and-rilpivirine-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-emtricitabine-and-tenofovir-alafenamide-detaf-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-lamivudine-and-tenofovir-alafenamide-tablets-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-dolutegravir-tablets-for-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-doxycycline-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-drospirenone-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-empagliflozin-linagliptin-and-metformin-hydrochloride-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-ivacaftor-oral-granules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-ivacaftor-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-letermovir-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-loteprednol-etabonate-ophthalmic-gel/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-migalastat-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-obeticholic-acid-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-olopatadine-hydrochloride-ophthalmic-solution-usp-0-7-otc/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-oxcarbazepine-er-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-raltegravir-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-rivaroxaban-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-selexipag-for-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-sitagliptin-and-metformin-hydrochloride-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-sitagliptin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-sodium-sulfate-magnesium-sulfate-and-potassium-chloride-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-tenofovir-alafenamide-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-tolvaptan-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-approval-from-u-s-fda-for-valbenazine-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-androgel-1-62/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-locoid-lotion/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-lurasidone-hydrochloride-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-nudovra/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approval-for-generic-tadalafil-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-fda-approvals-for-generic-nuvigil-tablets-and-generic-oracea-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-u-s-fda-approval-for-brivaracetam-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-u-s-fda-approval-for-dolutegravir-lamivudine-and-tenofovir-disoproxil-fumarate-tld-tablets-under-pepfar/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-u-s-fda-approval-for-fosaprepitant-for-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-us-fda-approval-for-dimethyl-fumarate-delayed-release-capsules-120-mg-and-240-mgn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-us-fda-approval-for-mirabegron-er-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-us-fda-approval-for-tadalafil-tablets-usp-20-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-tentative-us-fda-approval-for-ziprasidone/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-the-2014-astd-best-award-for-learning-development/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-divalproex-sodium-er-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-ethacrynic-acid-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-extended-phenytoin-sodium-capsules-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-fosaprepitant-for-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-hydrocortisone-valerate-cream/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-risperidone-long-acting-injectable-with-180-day-cgt-exclusivity-the-first-product-from-its-nanomis-long-acting-injectable-platform/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-sacubitril-and-valsartan-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-sevelamer-hydrochloride-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-uk-marketing-authorization-for-luforbec-100-6-µg-pmdi-first-branded-generic-alternative-to-fostair-100-6-µg-pmdi-for-treatment-of-asthma-copd/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-amlodipine-benazepril-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-amlodipine/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-cefadroxil-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-cefprozil-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-cinacalcet-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-clobazam-tablets-10-mg-and-20-mg/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-generic-lumigan-ophthalmic-solution-0-03/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-novel-formulation-of-suprax-suspension-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-novel-formulation-of-suprax-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-perindopril-erbumine-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-sertraline-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-sertraline/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-simvastatin-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approval-for-zileuton-extended-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-approvals-for-liraglutide-and-glucagon-injectable-products/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-us-fda-tentative-approval-for-memantine-hcl-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cefixime-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cefixime-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cefotaxime-sterile-vials-for-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-ceftriaxone-sterile-vials-for-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cefuroxime-axetil-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cephalexin-capsules/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-cephalexin-oral-suspension/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-divalproex-sodium-delayed-release-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-escitalopram-oxalate-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-levetiracetam-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-receives-usfda-approval-for-topiramate-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-resumes-sales-of-generic-fortamet/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-sales-and-operating-profit-up-22/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-secures-a-place-in-the-prestigious-sp-global-sustainability-yearbook-2025/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-sells-intellectual-property-on-perindopril-to-servier-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-sells-intellectual-property-on-perindopril-to-servier/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-settles-all-ongoing-litigation-with-sunovion-over-generic-of-lunesta-eszopiclone/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-settles-ongoing-litigation-with-medicis-over-generic-versions-of-solodyn/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-agreement-to-acquire-two-inhalation-brands-from-sunovion/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-an-agreement-with-csir-ncl-and-dst-for-the-development-of-a-continuous-manufacturing-process-for-biosimilar-monoclonal-antibody-therapeutic-mab/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-distribution-agreement-in-key-eu-territories-for-orphan-drug-namuscla/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-distribution-agreement-with-celnova-for-orphan-drug-namuscla/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-distribution-agreement-with-medis-for-orphan-drug-namuscla/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-exclusive-distribution-pact-with-fordoz-pharma-for-2-complex-injectable-assets-under-development/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-first-partnership-agreement-with-foncoo-for-china/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-mou-with-government-of-maharashtra-to-combat-rising-prevalence-of-cardiovascular-diseases-and-copd/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-mou-with-the-government-of-rajasthan-to-strengthen-healthcare-system/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-on-mary-kom-for-its-womens-cardiovascular-health-awareness-initiative-shakti/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-promotional-agreement-with-exeltis-on-solosec-secnidazole-expanding-access-for-adult-women-suffering-with-bacterial-vaginosis-and-adults-with-trichomoniasis/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-signs-strategic-agreement-with-farmanguinhos-brazil/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-strengthens-its-board-appoints-three-independent-directors/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-strengthens-its-global-specialty-ophthalmology-business-with-acquisition-of-visufarma-from-gho-capital/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-submits-marketing-authorization-application-for-etanercept-biosimilar-in-europe/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-submits-new-drug-application-for-etanercept-biosimilar-in-japan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-teams-up-with-mary-kom-to-raise-awareness-amongst-women-on-cardiovascular-disease/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-ties-up-with-leading-institutes-for-phd-program/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-to-acquire-51-stake-in-dafra/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-to-donate-yen-10-mn-for-japans-earthquake-victims/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-to-focus-on-the-development-of-inhalers-with-near-zero-global-warming-potential-propellants/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-to-market-new-inhaler-under-the-brand-name-loftair-in-india/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-to-reorganise-sale-structure-for-suprax/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-to-set-up-new-formulations-manufacturing-facility-in-mihan/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-to-set-up-new-lovastatin-plant-a-move-to-consolidate-presence-in-lifestyle-drugs/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-triples-research-spend/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-unveils-herbal-products/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-unveils-strategic-partnership-program-to-expand-reach-of-its-long-acting-injectable-platform/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-wins-award-for-operational-excellence-in-manufacturing-at-india-pharma-awards-2019/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-wins-five-indiastar-2020-awards-for-excellence-in-packaging/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-wins-india-packaging-award-for-corcal-bone-beauty/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-wins-india-pharma-leader-award-at-india-pharma-2020-and-india-medical-device-2020-conference/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-wins-packaging-award-for-its-patient-awareness-initiative-lupin-sahayak/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-wins-ramipril-product-patent-challenge-at-federal-circuit/ monthly 0.6 https://www.lupin.com/media/press-releases/lupinlife-collaborates-with-payal-singhal-and-mithali-raj-at-lakme-fashion-week-2020/ monthly 0.6 https://www.lupin.com/media/press-releases/lupinlife-launches-be-one-ayurvedic-energy-supplement/ monthly 0.6 https://www.lupin.com/media/press-releases/lupinlife-partners-with-uttarakhand-police-to-promote-hand-hygiene-at-kumbh-mela-2021-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupinlife-signs-hrithik-roshan-as-the-brand-ambassador-for-be-one-ayurvedic-energy-supplement/ monthly 0.6 https://www.lupin.com/media/press-releases/lupinlifes-be-one-wins-the-best-packaging-design-graphics-and-brand-value-add-award-at-the-india-packaging-awards-2021/ monthly 0.6 https://www.lupin.com/media/press-releases/lupinlifes-corcal-bone-beauty-to-launch-at-lakme-fashion-week/ monthly 0.6 https://www.lupin.com/media/press-releases/lupinlifes-lupisafe-announces-association-with-chennai-super-kings/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-alliance-partner-caplin-receives-u-s-fda-approval-for-rocuronium-bromide-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-alliance-partner-caplin-receives-u-s-fda-approval-for-thiamine-hydrochloride-injection-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-alliance-partner-concord-receives-approval-for-mycophenolic-acid-delayed-release-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-alliance-partner-concord-receives-u-s-fda-approval-for-mycophenolate-mofetil-tablets-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-alliance-partner-concord-receives-u-s-fda-approval-for-tacrolimus-capsules-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-alliance-partner-fordoz-receives-u-s-fda-approval-for-doxorubicin-hydrochloride-liposome-injection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-alliance-partner-natco-receives-fda-approval-for-generic-fosrenol-chewable-tablets/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-ankleshwar-facility-wins-frost-sullivans-india-manufacturing-excellence-awards-2019/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-ankleshwar-facility-wins-gold-award-from-american-society-for-quality-2/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-ankleshwar-facility-wins-par-excellence-award-at-33rd-national-convention-on-quality-concept/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-aptivate-champion-run-for-kids-receives-overwhelming-support/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-aurangabad-facility-inspection-concluded-by-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-aurangabad-facility-receives-eir-from-the-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-aurangabad-facility-receives-eir-from-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-brazilian-subsidiary-medquimica-acquires-rights-to-nine-brands-from-bausch-health/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-esg-score-rises-to-76-in-sp-global-esg-ratings/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-goa-facility-completes-successful-uk-mhra-inspection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-goa-facility-gets-approval-from-uk-mhra/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-goa-facility-inspection-concluded-by-us-fda-without-any-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-goa-manufacturing-plant-receives-eir-from-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-goa-non-cephalosporin-oral-dosage-facility-inspected-by-usfda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-humrahi-diabetes-support-program-expands-to-include-heart-health/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-inhalation-research-center-florida-receives-eir-from-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-joint-airways-initiative-surpasses-10000-patients/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-mandideep-facility-gets-approval-from-edqm/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-mandideep-unit-2-facility-completes-u-s-fda-inspection-with-no-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-mandideep-unit-ii-facility-receives-eir-from-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-nagpur-facility-inspection-by-us-fda-concluded-with-no-observation/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-nagpur-facility-receives-eir-from-the-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-nagpur-facility-receives-eir-from-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-nagpur-facility-receives-eir-from-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-nagpur-facility-receives-establishment-inspection-report-eir-from-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-nagpur-facility-us-fda-inspection-concluded-with-no-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-nagpur-facility-wins-enr-global-best-project-award/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-facilities-complete-successful-mhra-inspection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-facilities-complete-successful-uk-mhra-inspection/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-facility-inspection-concluded-by-us-fda-without-any-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-unit-1-facility-receives-eir-from-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-unit-1-facility-receives-establishment-investigation-report-eir-from-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-unit-3-indore-inspected-by-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-unit-3-indore-receives-eir-from-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-unit-3-indore-receives-eir-from-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pithampur-unit-cleared-by-health-canada/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-pune-biotech-facility-receives-eu-gmp-clearance/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-quarter-ii-fy2017-results/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-rd-facility-in-pune-awarded-leed-platinum-certification/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-softovac-in-the-economic-times-promising-brands-of-2018/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-somerset-manufacturing-plant-receives-eir-from-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-subsidiary-in-south-africa-announces-commercial-agreement-with-creso-pharma-for-hemp-oil-based-cannaqix/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-tarapur-api-manufacturing-facility-inspected-by-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-tarapur-facility-receives-eir-from-us-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-us-subsidiary-and-chester-valley-pharmaceuticals-decide-to-end-promotion-agreement/ monthly 0.6 https://www.lupin.com/media/press-releases/lupins-vizag-api-facility-receives-eir-from-u-s-fda/ monthly 0.6 https://www.lupin.com/media/press-releases/mr-edward-r-roberts-joins-lupin-board/ monthly 0.6 https://www.lupin.com/media/press-releases/mr-k-b-s-anand-and-dr-punita-kumar-sinha-join-lupin-board-as-independent-directors/ monthly 0.6 https://www.lupin.com/media/press-releases/msd-and-lupin-announce-strategic-partnership-to-co-market-msds-23-valent-pneumococcal-polysaccharide-vaccine-ppv-for-indian-market/ monthly 0.6 https://www.lupin.com/media/press-releases/nanomi-receives-cmo-award-for-life-science-leadership-in-drug-delivery/ monthly 0.6 https://www.lupin.com/media/press-releases/nhi-drug-price-listing-for-bipresso-extended-release-tablets-for-the-improvement-of-depressive-symptoms-associated-with-bipolar-disorder-announced/ monthly 0.6 https://www.lupin.com/media/press-releases/notice-of-3qfy20-earnings-call/ monthly 0.6 https://www.lupin.com/media/press-releases/notice-of-q2-fy2020-board-meeting/ monthly 0.6 https://www.lupin.com/media/press-releases/notice-of-q3-fy2020-board-meeting/ monthly 0.6 https://www.lupin.com/media/press-releases/notice-of-q3-fy2021-board-meeting/ monthly 0.6 https://www.lupin.com/media/press-releases/notice-of-q4-fy2020-board-meeting/ monthly 0.6 https://www.lupin.com/media/press-releases/notice-to-the-shareholders-2/ monthly 0.6 https://www.lupin.com/media/press-releases/notice-to-the-shareholders/ monthly 0.6 https://www.lupin.com/media/press-releases/orphan-drug-namuscla-receives-european-commission-approval-for-the-treatment-of-myotonia/ monthly 0.6 https://www.lupin.com/media/press-releases/press-release-alupin-receives-fda-approval-for-generic-nystatin-and-triamcinolone-acetonide-cream-usp/ monthly 0.6 https://www.lupin.com/media/press-releases/punita-lal-joins-lupin-board-as-additional-director/ monthly 0.6 https://www.lupin.com/media/press-releases/quarter-i-fy2018-results/ monthly 0.6 https://www.lupin.com/media/press-releases/quarter-i-fy2019-results/ monthly 0.6 https://www.lupin.com/media/press-releases/quarter-i-results-fy-2014-15/ monthly 0.6 https://www.lupin.com/media/press-releases/quarter-ii-results-fy-2014-15/ monthly 0.6 https://www.lupin.com/media/press-releases/quarter-iv-and-annual-results-fy2017/ monthly 0.6 https://www.lupin.com/media/press-releases/quarter-iv-and-annual-results/ monthly 0.6 https://www.lupin.com/media/press-releases/quarter-iv-annual-results-fy-2013-14-record-sales-and-profits/ monthly 0.6 https://www.lupin.com/media/press-releases/rajan-dutta-joins-lupin-as-president-hrd/ monthly 0.6 https://www.lupin.com/media/press-releases/record-sales-and-profits-quarter-iii-results-fy-2012-13/ monthly 0.6 https://www.lupin.com/media/press-releases/record-sales-and-profits/ monthly 0.6 https://www.lupin.com/media/press-releases/record-sales-profits-a-new-high-quarter-iv-annual-results/ monthly 0.6 https://www.lupin.com/media/press-releases/record-sales-profits-net-sales-up-44-pbt-up-67-pat-up-33-quarter-i-results-fy-2012-13/ monthly 0.6 https://www.lupin.com/media/press-releases/record-sales-profits-quarter-i-fy2017/ monthly 0.6 https://www.lupin.com/media/press-releases/record-sales-profits-quarter-ii-results-fy-2012-13-net-sales-up-29-ebitda-up-28-pbt-up-27-pat-up-9/ monthly 0.6 https://www.lupin.com/media/press-releases/robust-growth-record-profits-net-profit-up-24-q2-fy-2011-12/ monthly 0.6 https://www.lupin.com/media/press-releases/sanofi-aventis-multicare-ink-strategic-agreement-in-the-philippines/ monthly 0.6 https://www.lupin.com/media/press-releases/statement-on-media-reports-linking-sars-outbreak-with-demand-for-lupins-ribavirin/ monthly 0.6 https://www.lupin.com/media/press-releases/strong-growth-record-profits-quarter-iii-results-fy-2013-14-net-sales-up-21-ebitda-up-28-net-profit-up-42-declares-interim-dividend-of-150/ monthly 0.6 https://www.lupin.com/media/press-releases/strong-growth-robust-operating-performance/ monthly 0.6 https://www.lupin.com/media/press-releases/strong-margins-robust-profitability-quarter-i-results-fy-2013-14-ebitda-up-44-net-profit-up-43/ monthly 0.6 https://www.lupin.com/media/press-releases/strong-margins-robust-profits-quarter-iii-results-fy-2014-15/ monthly 0.6 https://www.lupin.com/media/press-releases/survey-data-reveals-the-need-for-improved-communication-between-patients-and-healthcare-providers/ monthly 0.6 https://www.lupin.com/media/press-releases/tb-alliance-and-lupin-announce-commercial-partnership-for-new-therapy-for-highly-drug-resistant-tb/ monthly 0.6 https://www.lupin.com/media/press-releases/the-40-crore-ai-payoff-how-lupin-is-building-a-data-first-ai-ready-pharma-enterprise/ monthly 0.6 https://www.lupin.com/media/press-releases/two-citigroup-representatives-join-lupins-board-2/ monthly 0.6 https://www.lupin.com/media/press-releases/two-citigroup-representatives-join-lupins-board/ monthly 0.6 https://www.lupin.com/media/press-releases/type-2-diabetes-boehringer-ingelheim-india-and-lupin-announce-strategic-co-marketing-agreement/ monthly 0.6 https://www.lupin.com/media/press-releases/u-s-fda-completes-inspection-of-lupins-aurangabad-facility-with-zero-observation/ monthly 0.6 https://www.lupin.com/media/press-releases/u-s-fda-completes-inspection-of-lupins-aurangabad-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/u-s-fda-completes-inspection-of-lupins-dabhasa-facility-with-no-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/u-s-fda-completes-inspection-of-lupins-vizag-facility-with-no-observations/ monthly 0.6 https://www.lupin.com/media/press-releases/u-s-fda-grants-mexiletine-orphan-drug-designation/ monthly 0.6 https://www.lupin.com/media/press-releases/us-fda-audit-at-lupins-dabhasa-facility-29th-june-06th-july-2016/ monthly 0.6 https://www.lupin.com/media/press-releases/us-fda-clears-lupins-mandideep-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/us-fda-completes-inspection-of-lupins-goa-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/us-fda-completes-inspection-of-lupins-mandideep-location/ monthly 0.6 https://www.lupin.com/media/press-releases/us-fda-completes-inspection-of-lupins-nagpur-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/us-fda-completes-inspection-of-lupins-pithampur-unit-2-indore-facility/ monthly 0.6 https://www.lupin.com/media/press-releases/lupin-foundation-earns-crisils-highest-vo-1a-rating-for-excellence-in-social-responsibility/ monthly 0.6 https://www.lupin.com/contact-us/ monthly 0.1 https://www.lupin.com/sitemap/ monthly 0.1 https://www.lupin.com/privacy-policy/ monthly 0.1 https://www.lupin.com/terms-of-service/ monthly 0.1 https://www.lupin.com/cookie-policy/ monthly 0.1 https://www.lupin.com/product-finder/ monthly 0.1